Pharmacologic management of overactive bladder

References

• AbramowiczM2001Detrol LA and Ditropan XL for overactive bladderMed Letter43289
   Google Scholar
• AbramowiczM2003Oxybutynin transdermal (Oxytrol) for overactive bladderMed Letter45389
   Google Scholar
• AbramsPCardozoLFallM2002The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence SocietyNeurourol Urodyn211677811857671
   PubMed Web of Science ®Google Scholar
• AppellRASandPDmochowskiR2001Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT studyMayo Clin Proc763586311322350
   PubMed Web of Science ®Google Scholar
• CardozoLLisecMMillardR2004Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladderJ Urol17219192415540755
   PubMed Web of Science ®Google Scholar
• ChappleCRRechbergerTAl-ShukriS2004Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily anti-muscarinic agent solifenacin in patients with symptomatic overactive bladderBJU Int9333031014764127
   PubMed Web of Science ®Google Scholar
• ChappleCRSteersWNortonP2005A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderBJU Int957993100115839920
   PubMed Web of Science ®Google Scholar
• ChappleCRMartine-GarciaRSelvaggiL2005A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome; results of the STAR trialEur Urol484647015990220
   PubMed Web of Science ®Google Scholar
• ChuFMDmochowskiR2006Pathophysiology of overactive bladderAm J Med1193S8S
   PubMed Web of Science ®Google Scholar
• DioknoACAppellRASandPK2003Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trialMayo Clin Proc786879512934777
   PubMed Web of Science ®Google Scholar
• DmochowskiRRSandPKZinnerNR2003Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinenceUrology622374212893326
   PubMed Web of Science ®Google Scholar
• ErdemNChuFM2006Management of overactive bladder and urge urinary incontinence in the elderly patientAm J Med11929S36S
   PubMed Web of Science ®Google Scholar
• GittelmanMChuFMKlimbergI2003Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladderJ Urol169349
   Web of Science ®Google Scholar
• HaabFStewartLDwyerP2004Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladderEur Urol454420915041104
   PubMed Web of Science ®Google Scholar
• HaabFCardozoLChappleC2005Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndromeEur Urol473768415716204
   PubMed Web of Science ®Google Scholar
• HerbisonPHay-SmithJEllisG2003Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladderBMJ326841412702614
   PubMed Web of Science ®Google Scholar
• HillSKhullarVWyndaeleJJ2006Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose studyInt Urogynecol J Pelvic Floor Dysfunct1732394715999217
   PubMed Web of Science ®Google Scholar
• HuTWWagnerTHBentkoverJD2003Estimated economic costs of overactive bladder in the United StatesUrology611123812809878
   PubMed Web of Science ®Google Scholar
• KelleherCJCardozoLChappleCR2005Improved quality of life in patients with overactive bladder symptoms treated with solifenacinBJU Int9581515638900
   PubMed Web of Science ®Google Scholar
• OuslanderJG2002Geriatric considerations in the diagnosis and management of overactive bladderUrology6050512493354
   PubMed Web of Science ®Google Scholar
• OuslanderJG2004Management of overactive bladderN Engl J Med3507869914973214
   PubMed Web of Science ®Google Scholar
• Product Information2004a Ditropan XL®, oxybutynin chloride extended-release tablets. Ortho-McNeil Pharmaceutical, Inc., New Jersey, USA.
   Google Scholar
• Product Information2004b Enablex®, darifenacin. Novartis Pharmaceuticals Corporation, New Jersey, USA.
   Google Scholar
• Product Information2004c Sanctura®, trospium. Esprit, New Jersey, USA.
   Google Scholar
• Product Information2004d VESIcare®, solifenacin. Yamanouchi Pharma America, Inc. and GlaxoSmithKline, Oklahoma & New Jersey, USA.
   Google Scholar
• Product Information2005 Detrol LA®, tolterodine tartrate extended-release capsules. Pfizer Inc., New York, USA.
   Google Scholar
• RizackMA2005Solifenacin and darifenacin for overactive bladderMed Letter47234
   Google Scholar
• RudyDClineKHarrisR2006Multicenter phase III trial studying trospium chloride in patients with overactive bladderUrology672758016461077
   PubMed Web of Science ®Google Scholar
• RudyDClineKHarrisR2006Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatmentBJU Int97540616469022
   PubMed Web of Science ®Google Scholar
• SimpsonDWagstaffAJ2005Solifenacin in overactive bladder syndromeDrugs Aging221061916363887
   PubMed Web of Science ®Google Scholar
• StaskinDRMacDiarmidSA2006Pharmacologic management of overactive bladder: practical options for the primary care physicianAm J Med11924S8S
   PubMed Web of Science ®Google Scholar
• StaskinDRMacDiarmidSAUsing anticholinergics to treat overactive bladder: the issue of treatment tolerabilityAm J Med20061199S15S
   PubMed Web of Science ®Google Scholar
• SteersWCorcosJFooteJ2005An investigation of dose titration with darifenacin, an M3-selective receptor antagonistBJU Int95580615705084
   PubMed Web of Science ®Google Scholar
• StewartWFVan RooyenJBCundiffGW2003Prevalence and burden of overactive bladder in the United StatesWorld J Urol203273612811491
   PubMed Web of Science ®Google Scholar
• SussmanDGarelyA2002Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)Curr Med Res Opin181778412201616
   PubMed Web of Science ®Google Scholar
• TodorovaAVonderheid-GuthBDimpfelW2001Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemJ Clin Pharmacol416364411402632
   PubMed Web of Science ®Google Scholar
• ZinnerNGittelmanMHarrisR2004SussetJKanelosAAuerbachSTrospium chloride improves overactive bladder symptoms: a multicenter phase III trialJ Urol1712311515126811
   PubMed Web of Science ®Google Scholar
• ZinnerNTuttleJMarksL2005Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladderWorld J Urol232485216096831
   PubMed Web of Science ®Google Scholar